Oral N-acetylcysteine for Retinitis Pigmentosa
NCT05537220
Recruiting
Retinitis pigmentosa (RP) is an inherited retinal degeneration caused by one of several mistakes in the genetic code. Such mistakes are called mutations. The mutations cause degeneration of rod photoreceptors which are responsible for vision in dim illumination resulting in night blindness. After rod photoreceptors are eliminated, gradual degeneration of cone photoreceptors occurs resulting in gradual constriction of side vision that eventually causes tunnel vision. Oxidative stress contributes... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
11/30/2023
Locations: University of Iowa, Carver College of Medicine, Iowa City, Iowa
Conditions: Retinitis Pigmentosa
Register for Updates
An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration
NCT05300724
Recruiting
This is a multicenter prospective study in participants with intermediate age-related macular degeneration (iAMD). One primary objective of this study is to assess iAMD disease progression, by the timeline and rates of conversion for high-risk iAMD at baseline to more advanced atrophic AMD stages. The other primary objective of this observational study is to assess the feasibility of measuring the rate of photoreceptor loss as a potential clinical endpoint. The study will consist of an observati... Read More
Gender:
All
Ages:
Between 50 years and 94 years
Trial Updated:
11/30/2023
Locations: Wolfe Eye Clinic, West Des Moines, Iowa
Conditions: Age-Related Macular Degeneration
Register for Updates
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
NCT05126758
Recruiting
HOPE-3 is a two cohort, Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a cell therapy called CAP-1002 in study participants with Duchenne muscular dystrophy (DMD) and impaired skeletal muscle function. Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either CAP-1002 or placebo every 3 months for a total of 4 doses during the first 12-months of the study. Al... Read More
Gender:
Male
Ages:
10 years and above
Trial Updated:
11/30/2023
Locations: University of Iowa Hospitals and Clinics, Iowa City, Iowa
Conditions: Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn, Nervous System Diseases
Register for Updates
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
NCT05058651
Recruiting
This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide versus standard therapy alone for the treatment of poorly differentiated extrapulmonary (originated outside the lung) neuroendocrine cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary s... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Mary Greeley Medical Center, Ames, Iowa
Conditions: Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma, Unresectable Extrapulmonary Neuroendocrine Carcinoma
Register for Updates
Stroke Thrombectomy and Aneurysm Registry
NCT04994756
Recruiting
This international multi-center registry is used to collect existing information and outcomes for patients undergoing an operation for treatment of injuries to the brain including the blockage of blood flow to an area of the brain, an abnormal ballooning of an artery, abnormal tangling of blood vessels, abnormal formation of blood vessels, tearing of vein, and bleeding in the brain. This information is used to help predict outcomes that undergo an operation for treatment of the above-listed brai... Read More
Gender:
All
Ages:
Between 1 year and 120 years
Trial Updated:
11/30/2023
Locations: University of Iowa, Iowa City, Iowa
Conditions: Stroke, Thromboses, Intracranial, Aneurysm, Brain
Register for Updates
Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy
NCT04984876
Recruiting
This is a 52-week, Phase 3 multi-center, randomized, double-blind and placebo-controlled study to assess the safety and clinical efficacy of two dosing regimens of ligelizumab (240 mg and 120 mg) subcutaneous injection every 4 weeks (SCq4w) in participants with a medically confirmed diagnosis of IgE-mediated peanut allergy.
Gender:
All
Ages:
Between 6 years and 55 years
Trial Updated:
11/30/2023
Locations: Novartis Investigative Site, Iowa City, Iowa
Conditions: Allergy, Peanut
Register for Updates
A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.
NCT04936542
Recruiting
This study is aiming to demonstrate the non-inferiority of AbobotulinumtoxinA (aboBoNT-A) versus OnabotulinumtoxinA (onaBoNT-A) as the primary safety endpoint, and the superiority of aboBoNT-A over onaBoNT-A with respect to duration of response as the key secondary efficacy endpoint when used at optimal doses according to approved prescribing information of each product.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
11/30/2023
Locations: McFarland Clinic PC, Ames, Iowa
Conditions: Upper Limb Spasticity
Register for Updates
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
NCT04924075
Recruiting
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per Response... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
11/30/2023
Locations: University of Iowa ( Site 0104), Iowa City, Iowa
Conditions: Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor, HIF-2α Mutated Cancers
Register for Updates
Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)
NCT04922554
Recruiting
The purpose of this study is to evaluate the efficacy, safety and tolerability of oral omadacycline as compared to placebo in the treatment of adults with Nontuberculous Mycobacterial (NTM) pulmonary disease caused by Mycobacterium abscessus complex (MABc)
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: University of Iowa Hospitals and Clinics, Iowa City, Iowa
Conditions: Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection
Register for Updates
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
NCT04699838
Recruiting
The primary objective of this single arm study is to estimate the progression free survival of previously-untreated patients with extensive stage small cell lung cancer. Patients will receive initial chemo-immunotherapy followed by maintenance therapy with durvalumab and oral ceralasertib.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: University of Iowa Hospitals and Clinics, Iowa City, Iowa
Conditions: Extensive Stage Small Cell Lung Cancer
Register for Updates
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)
NCT04609878
Recruiting
This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
11/30/2023
Locations: Research Site, West Des Moines, Iowa
Conditions: Asthma
Register for Updates
Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
NCT04578834
Recruiting
The study is designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Novartis Investigative Site, Iowa City, Iowa
Conditions: IgA Nephropathy
Register for Updates